I.N. BOKARYOV, L.V. POPOVA

Sechenov First Moscow State Medical University, 8 Trubetskaya St., building 2, Moscow, Russian Federation 119991

Popova L.V. — Cand. Med. Sc., Associate Professor of the Department of Hospital Therapy № 1, tel. (495) 471-27-20, e-mail: mila_foka@mail.ru

Bokaryov I.N. —D. Med. Sc., Head of the Laboratory for Thrombosis, Thrombophilia and Haemostasis Pathology, Professor of the Department of Hospital Therapy № 1, tel. (495) 471-33-59, e-mail: bokarevin@yandex.ru 

The leading cause of death for people throughout the world is atherothrombosis of various localization. One of the key moments of the struggle with this pathology is the application of antiplatelet agents. These drugs differ in the mechanism of platelet function inhibition. Acetylsalicylic acid, ADP-receptor blockers R2Y12 (ticlopidine, clopidogrel, prasugrel, tikaglerol), glycoprotein antagonists IIb/IIIa for intravenous injection, and dipyridamole have the most optimal ratio of effcetiveness and security, which allows to use them in clinical practice.

Key words: atherothrombosis, antiplatelet agents, acetylsalicylic acid, ticlopidine, clopidogrel, prasugrel, tikaglerol, , glycoprotein antagonists IIb/IIIa for intravenous injectionn, dipyridamole.

 

 

REFERENCES

1. What Is Aspirin? What Is Aspirin For, available at: http://www.medicalnewstoday.com/articles/161255.php

2. Fuster V., Sweeny J.M. Aspirin: A Historical and Contemporary Therapeutic Overview. Circulation, 2011, vol. 123, pp. 768-778 doi: http://circ.ahajournals.org/

3. Schlager N., Weisblatt J., Newton D.E., editors, Chemical Compounds? Thomson Gale. China, 2006. P. 981.

4. Gawaz M., editor. Blood platelets — clinical relevance. Stuttgart: Georg Thieme Verlag; 2010.

5. Hemler M., Lands W.E., Smith W.L. Purification of the cyclooxygenase that forms prostaglandins: demonstration of two forms of iron in the holoenzyme. J Biol Chem., 1976, vol. 251, pp. 5575-5579.

6. Patrono C., Ciabattoni G., Patrignani P. et al. Clinical phar¬macology of platelet cyclooxygenase inhibition. Circulation, 1985, vol. 72, no. 6, pp. 1177-1184.

7. Pedersen A.K., FitzGerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. The New England Journal of Medicine, 1984, vol. 311, no. 19, pp.1206-1211.

8. Patrono C., Baigent C., Hirsh J., Roth G. Ap Drugs. Chest, 2008, 133 (6 suppl), pp. 199-233. Antithrombotic Trialists’ (ATT) Collaboration. Lancet, 2009, vol. 373, pp. 1849-60.

9. Peters R.J., Mehta S.R., Fox K.A. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation, 2003, vol. 108, pp. 1682-1687.

10. Steinhubl S.R., Bhatt D.L., Brennan D.M. et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med., 2009, vol. 150, pp. 379-386.

11. Primary and Secondary Prevention of Cardiovascular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guideline. Chest, 2012, vol. 141 (2) (Suppl), pp. 637-668.

12. Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMj., 1995, vol. 310, pp. 827-830.

13. Yeomans N.D., Lanas A.I., Talley N.J. et al. Prevalence and incidence of gastroduodenal ulcers dur-ng treatment with vascular protective doses of aspirin, Aliment Pharmacol Ther., 2005, vol. 22, pp. 795-801.

14. Abraham N.S., Hartman C., Castillo D. et al. Effectiveness of national provider prescription of PPI gas-troprotection among elderly NSAID users, Am J Gastroenterol., 2008, vol. 103, pp. 323-332.

15. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice, Lancet, 2001, vol. 357, pp. 89-95.

16. Kelly J.P., Kaufman D.W., Jurgelon J.M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product, Lancet, 1996, vol. 348, pp. 1413-1416.

17. Sung J.J., Lau J.Y., Ching J.Y., Wu J.C. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial, Ann Intern Med., 2010, vol. 152, pp. 1-9.

18. Awtry E., Loscalzo J. Aspirin, Circulation, 2000, vol. 101, pp. 1206-1218.

19. Petrucci R.B., Petrucci G. Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms, Thrombosis, vol. 2012. Article ID 376721, 11 pages doi:10.1155/2012/376721

20. Sagar K., Smyth M. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography, J Pharm Biomed Anal., 1999, Nov., vol. 21 (2), pp. 383-92.

21. de Abajo F.J., Garcia Rodriguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations, BMC Clinical Pharmacology, 2001, vol. 1, article 1.

22. Garcia Rodriguez L.A., Cattaruzzi C. et. al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal and anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs, Arch. Intern. Med., 1998, vol. 158, pp. 33-39.

23. Damann H.G. Gastroduodenal tolerability profile of low dose enteric coated ASA, Gastroenter., Int. 1998, vol. 11, pp. 205-16.

24. Chan F.K., Chung S.C. et al. Preventing recurrent upper gastrointestinal bleeding in patient with Helicobacter pylori infection who are taken low dose aspirin or naproxen, N. Engl. J. Med., 2001, vol. 344, pp. 967-973.

25. Wiviott S.D., Braunwald E., McCabe C.H. et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, N Engl J Med., 2007, November 15, vol. 357, pp. 2001-15.

26. Cannon C.P., Harrington R.A., James S. et al, for PLATO investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive stategy for acute coronary syndromes (PLATO): a randomized double-blind study, Lancet, 2010, vol. 375, pp. 283-293.

27. Hamm C.W., Bassand J.-P., Agewall S. at al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) European Heart Journal, 2011, vol. 32, pp. 2999-3054.

28. Steg G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) European Heart Journal, 2012, vol. 33, pp. 2569-2619.

29. Guyatt G.H., Akl E.A., Crowther M. et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, 2012, vol. 141. Pp. 7S-47S.

30. McCain J. Choosing the Right Oral Antiplatelet Medication ANAGED CARE November 2013. © MediMedia USA, available at: http://www.managedcaremag.com/

31. Drepper M.D., Spahr L., Frossard J.L. clopidogrel and proton pump inhibitions — where do we stand in 2011?, World J Gastroenterol., 2012, May 14, 18 (18).

32.Abraham N.S., Hartman C., Castillo D. et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users, Am J Gastroenterol., 2008, vol. 103, pp. 323-332.

33. Ferreiro J.L., Ueno M., Tomasello S.D. et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study, Circ Cardiovasc Interv., 2011, vol. 4, pp. 273-279.

34. Lettino M. Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?, Eur J Intern Med., 2010, vol. 21, pp. 484-489.

35. Nguyen T.A., Diodati J.G., Pharand C.l. Resistance to Clopidogrel, A Review of the Evidence Journal of the American College of Cardiology. — 2005. — Vol. 45, No. 8.

36.Collet J.P., Hulot J.S., Pena A. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, Lancet, 2008, available at: http://www.thelancet.com

37. Simon T., Verstuyft C., Mary-Krause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events, N. Engl. J. Med., 2009, available at: http//www.nejm.org

38. Mega J.L., Close S.L., Wiviott S.D. et al. Cytochrome P-450 polymorphisms and response to Clopidogrel, N. Engl. J. Med., 2009. DOI: 10.1056/NEJMoa0809171. Available at: http://www.nejm.org

39. Wijns W., Kolh Ph., Danchin N. et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal, 2010, vol. 31, pp. 2501-2555.

40. Wallentin L., James S., Storey R.F. et al. Effect of CYP2C19 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial, Lancet, 2010. Epub ahead of print. Also presented at: ESC Congress. 2010, August 29. 2010, Stockholm, Sweden.

41. Verro P., Gorelick P.B., Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis, Stroke, 2008, Apr., vol. 39 (4), pp. 1358-63.

42. De Schryver E.L., Algra A., van Gijn J. Dipyridamole Dipyridamole for preventing stroke and other vascular events in patients with vascular disease, 2008, Nov., vol. 79 (11), pp. 1218-23.

43. Pannu R., Andraws R. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials, Crit Pathw Cardiol., 2008, Mar., vol. 7 (1), pp. 5-10.